Prenatal biochemical screening.
Most fetal abnormalities occur in low-risk pregnancies. Screening techniques have been developed to help determine who in the low-risk group may actually be at high risk. Biochemical screening for chromosomal abnormalities and neutral tube defects have significantly increased their detection, but there is still considerable room for improvement.
Drugan
A
A
Department of Obstetrics and Gynecology, Hutzel Hospital/Wayne State University, Detroit, Michigan 48201.
O'Brien
J E
JE
Gambino
R S
RS
Evans
M I
MI
D000649:Amniocentesis / Q000592:standards; D006063:Chorionic Gonadotropin / Q000097:blood; D000013:Congenital Abnormalities / Q000097:blood* / Q000175:diagnosis / Q000453:epidemiology; D004964:Estriol / Q000097:blood; D005260:Female; D030342:Genetic Diseases, Inborn / Q000097:blood* / Q000175:diagnosis / Q000453:epidemiology; D006801:Humans; D008403:Mass Screening / Q000379:methods / Q000592:standards*; D008423:Maternal Age; D011247:Pregnancy; D015995:Prevalence; D012680:Sensitivity and Specificity; D016216:Ultrasonography, Prenatal; D000509:alpha-Fetoproteins / Q000737:chemistry
D006063:Chorionic Gonadotropin; D000509:alpha-Fetoproteins; D004964:Estriol